CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell medicines, including EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia.
{iframe}http://www.globenewswire.com/news-release/2019/10/07/1925712/0/en/Editas-Medicine-and-MaxCyte-Announce-Clinical-and-Commercial-License-Agreement-for-Engineered-Cell-Medicines.html{/iframe}